TY  - JOUR
T1  - Delayed reversible methotrexate-induced leucoencephalopathy in a four-year-old child with acute lymphoblastic leukemia
A1  - Amrita Roy
A1  - Neelakshi Ghosh
A1  - Aramita Saha
A1  - Somenath Chatterjee
JF  - Clinical Cancer Investigation Journal
JO  - Clin Cancer Investig J
SN  - 2278-0513
Y1  - 2013
VL  - 2
IS  - 2
DO  - 10.4103/2278-0513.113642
SP  - 160
EP  - 162
N2  - Intravenous/intrathecal methotrexate (MTX) has been implicated as a major cause of treatment-related neurotoxicity particularly leukoencephalopathy in children with hematological malignancy. We report a 4-year-old boy who presented with apathy and aphasia for 1 day while on the maintenance-phase chemotherapy according to MCP 841 protocol. MRI of brain revealed bilateral symmetrical FLAIR hyperintensities in caudate and putaminal region with FLAIR hypersignal in subcortical U-fiber in left frontal lobe consistent with MTX-induced toxic leucoencephalopathy. There was spontaneous resolution of symptoms within 1 week of onset. So, in Pre-B acute lymphoblastic leukemia patients with subtle neurological deficit, this diagnosis should be kept in mind and further treatment with MTX should be carefully decided.
UR  - https://ccij-online.org/article/delayed-reversible-methotrexate-induced-leucoencephalopathy-in-a-four-year-old-child-with-acute-lymphoblastic-leukemia-105
ER  -